On some cases our legal team able to handle all kinds of marine claims arising
during and after vessels calling Algerian/Tunisian ports such as:

  • Fines / Breaches of port regulations
  • Legal proceedings & recovery claims
  • Damages to port installations property Freight disputes
  • Letters of Undertaking / guarantees
  • FDD & FFO claims
LEGAL

Associate Professor Georgina Long

Associate Professor Georgina Long BSc PhD MBBS FRACP is a Clinical Researcher and Medical Oncologist at Melanoma Institute Australia, University of Sydney. Georgina has presented her work at international conferences and meetings on more than 100 occasions.

Georgina is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular focus on clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance. In recognition of her ground breaking research, Associate Professor Long has received a number of awards at the CINSW Premier Awards for Outstanding Cancer Research: in 2014, she was awarded the Wildfire Award for the most highly cheap jerseys cited, original, peer reviewed article published in 2011, and in 2013 was the Outstanding Cancer Research Fellow. Georgina is also the recipient of a Cancer Institute NSW Fellowship, was awarded a University Medal in Chemistry prior to commencing a PhD in Chemistry and medical studies (MBBS) at the University of Sydney, and was awarded a Fulbright Postdoctoral Fellowship at Scripps Research Institute, USA. Georgina became a Fellow of the Australasian College of Physicians after completing Medical Oncology training in Sydney, Australia.

Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., Long, G., et al (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. New England Journal of Medicine, 372(1), 30 39. [More Information]

Phan, T., Long, G., Scolyer, R. (2015). Multiple checkpoints on the long road towards cancer immunotherapy. Immunology and Cell Biology, 93(4), 323 325. [More Information]

Robert, C., Long, G., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J., Rutkowski, P., McNeil, C., Kalinka Warzocha, E., et al (2015). Nivolumab in Previously Untreated Melanoma without BRAF Mutation. The New England Journal of Medicine, 372(4), 320 330. [More Information]

Carlino, M., Fung, C., Shahheydari, H., Todd, J., Boyd, S., Irvine, M., Nagrial, A., Scolyer, R., Kefford, R., Long, G., Rizos, cheap jerseys H. (2015). Pre existing MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Clinical Cancer Research, 21(1), 98 105. [More Information]

Shi, H., Hong, A., Kong, X., Koya, R., Song, C., Moriceau, G., Hugo, W., Yu, C., Ng, C., Chodon, T., wholesale cheap jerseys Scolyer, R., Kefford, R., Long, G., et al (2014). A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discovery, 4(1), 69 79. [More Information]

Anforth, R., Liu, M., Nguyen, B., Uribe, P., Kefford, R., Clements, A., Long, G., Fernandez Penas, P. (2014). Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib. The Australasian Journal of Dermatology, 55(4), 250 254. [More Information]

Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R., Moriceau, G., Chodon, T., Guo, R., Johnson, D., Dahlman, K., Kefford, R., Long, G., et al (2014). Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discovery, 4(1), 80 93. [More Information]

Bowyer, S., Rao, A., Lyle, M., Sandhu, S., Long, G., McArthur, G., Raleigh, J., Hicks, R., Millward, M. (2014). Activity of trametinib in K601E and L597Q BRAF mutation positive metastatic melanoma. Melanoma Research, 24(5), 504 508. [More Information]

Rizos, H., Menzies, A., Pupo, G., Carlino, M., Fung, C., Hyman, J., Haydu, L., Mijatov, B., Becker, T., Boyd, S., Howle, J., Saw, R., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research, 20(7), 1965 1977. [More Information]

Johnson, D., Flaherty, K., Weber, J., Infante, J., Kim, K., Kefford, R., Hamid, O., Schuchter, L., Cebon, J., Sharfman, W., Long, G., et al (2014). Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600 mutant melanoma experiencing progression with single agent BRAF inhibitor. Journal of Clinical Oncology, 32(33), 3697 3704. [More Information]

Long, G., Stroyakovskiy, D., Gogas, H., Levchenko, E., De Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J., et al (2014). Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. The New England Journal of Medicine, 371(20), 1877 1888. [More Information]

Kakavand, H., Crainic, O., Lum, T., O’Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193 198. [More Information]

Carlino, M., cheap nfl jerseys Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W., Thompson, J., Kefford, R., O’Toole, S., Scolyer, R., Long, G. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292 299. [More Information]

Menzies, A., Long, G. (2014). Dabrafenib and Trametinib, Alone and in Combination for BRAF Mutant Metastatic Melanoma. Clinical Cancer Research, 20(8), 2035 2043. [More Information]

Carlino, M., Todd, J., Gowrishankar, K., Mijatov, B., Pupo, G., Fung, C., Snoyman, S., Hersey, P., Long, G., Kefford, R., Rizos, H. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 8(3), 544 554. [More Information]

Falchook, G., Long, G., Kurzrock, R., Kim, K., Arkenau, H., Brown, M., Hamid, O., Infante, J., Millward, M., Pavlick, A., Kefford, R., et al (2014). Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 20(17), 4449 4458. [More Information]

Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF mutant melanoma patients during BRAF inhibitor treatment. The Journal of Immunology, 192(5), 2505 2513. [More Information]

Lezcano, C., Lee, C., Larson, A., Menzies, A., Kefford, R., Thompson, J., Mihm, M., Ogino, S., Long, G., Scolyer, R., et al (2014). Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Modern Pathology, 27(9), 1193 1202. [More Information]

Lee, C., Menzies, A., Haydu, L., Azer, M., Clements, A., Kefford, R., Long, G. (2014). Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Research, 24(5), 468 474. [More Information]

Zimmer, L., Haydu, L., Menzies, A., Scolyer, R., Kefford, R., Thompson, J., Schadendorf, D., Long, G. (2014). Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. Journal of Clinical Oncology, 32(8), 816 823. [More Information]

Long, G., Fung, C., Menzies, A., Pupo, G., Carlino, M., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J., Saw, R., Howle, J., Scolyer, R., Kefford, R., Rizos, H., et al (2014). Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma. Nature Communications, 5, 1 9. [More Information]

Gopal, V., Rizos, H., Chen, G., Deng, W., Frederick, D., Cooper, Z., Scolyer, R., Pupo, G., Komurov, K., Sehgal, V., Long, G., et al (2014). Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1 and oxidative phosphorylation in melanoma. Cancer Research, 74(23), 7037 7047.

Menzies, A., Haydu, L., Carlino, M., Azer, M., Carr, P., Kefford, R., Long, G. (2014). Inter and Intra Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma. PloS One, 9(1), 1 9. [More Information]

Menzies, A., Wilmott, J., Long, G., Scolyer, R. (2014). Intra patient heterogeneity of BRAF mutation status: fact or fiction? British Journal of Cancer, 111(8), 1678 1679. [More Information]

Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O’Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377 382. [More Information]

De Sousa, S., Long, G., Tonks, K. (2014). Ipilimumab induced hypophysitis: early Australian experience. Medical Journal of Australia, 201(4), 189 199. [More Information]

Ackerman, A., Klein, O., McDermott, D., Wang, W., Ibrahim, N., Lawrence, D., Gunturi, A., Flaherty, K., Hodi, F., Kefford, R., Menzies, A., Long, G., et al (2014). Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer, 120(11), 1695 1701. [More Information]Articles Connexes:


laws we know the discount michael kors sale contents of the replica Michael Kors two bottles are identical. As to flavor, there’s no detectable difference. Possibly both are manufactured and bottled together in the same plant and from the same spigot. Keep this in mind as you shop. Ignore high pressure promotion. A person’s possessions speak volumes on what the individual considers important. The advertising industry, devoted to identifying fake michael kors what the citizen considers significant, manipulates the market to create those choices. With massive sums cheap michael kors to be spent, the competition is as fierce as it is grotesque. And replica cheap Michael Kors what is pushed? Magazine subscriptions, timeshare projects, $300 per ounce bottles of perfume, Las Vegas weekend getaways, $1,800 ballpoint pens, and the purchase of lottery tickets, to name just a few. As a rule of thumb, the more overpriced the merchandise, the more innovative its promotion. Don’t be a victim. Resist discount michael kors store the new vehicle lure. With the exception of hearth and cheap michael kors home, the motor cheap Michael Kors vehicle constitutes the average American’s single most important
Thomas Crown Affair Thomas Crown Affair seems to take its cues from Bill Conti score: It sprightly, frisky and unexpectedly playful. Conti clears away the bombast that usually clutters his music just as director John McTiernan has cleared away the depressingly familiar clichis of big budget entertainments. Thomas Crown Affair may turn out to be the most entertaining American movie of the summer, and there isn a car chase, a shootout or unless you count a few smoke cheap michael kors bags bombs an explosion in sight. In other words, McTiernan pays the audience the supreme compliment of thinking they be kept awake by wit and sexiness and the allure of his two stars, Pierce Brosnan and Rene Russo, both of them shot like the most irresistible items on the most tempting dessert cart imaginable. Part caper picture, part cat and mouse romance, this remake of the 1968 picture starring Steve McQueen and Faye Dunaway is closer in spirit discount michael kors to what the Bond movies used to be. It a deluxe vacation for adults with all frills included: glamorous settings,
Articles Connexes:

Social networks

Newsletter

Back to Top